P-003. Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir±Ribavirin treatment in HCV infected chronic hemodialysis patients: A single center experience

INTRODUCTION: The prevelance of HCV in Turkey is 0.5–1.0%. According to Turkish Society of Nephrology registry, anti-HCV positivity rate was 6.94% in chronic hemodialysis patients in 2013. Beyond the liver-related mortality, HCV infection increases all kind of mortality in hemodialysis patients. In...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Turk J Gastroenterol
Hoofdauteurs: Danis, Nilay, Pullukcu, Husnu, Yamazhan, Tansu, Ersoz, Galip, Unal, Nalan Gülsen, Gunsar, Fulya, Turan, Ilker, Karasu, Zeki, Akarca, Ulus Salih
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Turkish Society of Gastroenterology 2019
Onderwerpen:
AASLD - TASL CONNECT REGIONAL MEETING, March 15–16, 2019 - İstanbul, Turkey
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021023/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/tjg.2019.09
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items